Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab

Part of paid clinical trials in Bakersfield, California.

Sponsor
University of California, San Diego
Study ID
NCT01402544
Phase
PHASE2/PHASE3
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ranibizumab — DRUG
    0.5mg intravitreal injection, monthly for 12 months, or until BCVA returns to pre-wet AMD baseline.

Study Details

To determine if patients treated early after diagnosis of wet age-related macular degeneration can return/maintain to their baseline pre-disease BCVA.

Key Dates

First listed
Jul 26, 2011
Start date
Jul 31, 2011
Status verified
Aug 2019
Primary completion
Mar 31, 2015
Completion
Mar 31, 2015

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Ranibizumab 0.5 mg
    Ranibizumab 0.5 mg Intravitreal Injection, monthly, open-label, for the duration of 1 year

Primary Outcome Measure

Number of Patients That Achieve Their Pre-wet Age-Related Macular Degeneration (AMD) Baseline Visual Acuity Within 12 Months [ Time Frame: Baseline, Month 6 and Month 12 ]

Locations (4)

FacilityCityStateZIPSite coordinators
California Retina ConsultantsBakersfieldCalifornia93309-
Shiley Eye Center, UCSDLa JollaCalifornia92093-
California Retina ConsultantsSanta BarbaraCalifornia93103-
Medical Center Ophthalmology AssociatesSan AntonioTexas78240-

Find similar trials in Bakersfield, CA

By condition
Age-related macular degeneration
By specialty
OphthalmologyRetina
By research site
California Retina Consultants· Bakersfield, CAShiley Eye Center, UCSD· La Jolla, CACalifornia Retina Consultants· Santa Barbara, CAMedical Center Ophthalmology Associates· San Antonio, TX

Related Studies